Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

Overview of attention for article published in British Journal of Haematology, May 2009

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

policy: 2 policy sources

guideline: 3 clinical guideline sources

Readers on

mendeley: 58 Mendeley

So far, Altmetric has seen 5 policy documents that reference this research output.

Opdivo for classical Hodgkin Lymphoma (after failure of ASCT) – Details - Nivolumab (Opdivo) cHL- Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 29 Sep 2017

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Adcetris for Hodgkin’s Lymphoma (post-ASCT) Resubmission – Details - Brentuximab (Adcetris) HL (post-ASCT) Resubmission – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 10 Aug 2017

Pembrolizumab (Keytruda) classical Hodgkin Lymphoma – Details - Pembrolizumab (Keytruda) cHL - Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 07 Jul 2017

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma: Committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 06 Mar 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity, including 1 additional policy documents.